SLI
1.984,39
PKT
-17,19
PKT
-0,86
%
Werbung
Analysen zu SLI-Werten
Datum | Rating | Analyst | |
---|---|---|---|
31.10.19 | Swiss Re overweight | Barclays Capital | |
31.10.19 | Swiss Re buy | Goldman Sachs Group Inc. | |
31.10.19 | Novartis Hold | Deutsche Bank AG | |
31.10.19 | UBS buy | Deutsche Bank AG | |
31.10.19 | Swiss Re Sell | UBS AG | |
31.10.19 | UBS Neutral | JP Morgan Chase & Co. | |
30.10.19 | Holcim buy | Goldman Sachs Group Inc. | |
30.10.19 | Givaudan Sell | Goldman Sachs Group Inc. | |
30.10.19 | UBS buy | Goldman Sachs Group Inc. | |
30.10.19 | UBS Equal weight | Barclays Capital | |
30.10.19 | UBS Neutral | JP Morgan Chase & Co. | |
30.10.19 | UBS Equal weight | Barclays Capital | |
30.10.19 | UBS Equal-Weight | Morgan Stanley | |
30.10.19 | UBS Sector Perform | RBC Capital Markets | |
30.10.19 | Novartis Underweight | JP Morgan Chase & Co. | |
30.10.19 | UBS buy | UBS AG | |
30.10.19 | Holcim overweight | JP Morgan Chase & Co. | |
29.10.19 | Holcim Equal weight | Barclays Capital | |
29.10.19 | ABB (Asea Brown Boveri) Underweight | JP Morgan Chase & Co. | |
28.10.19 | Holcim overweight | JP Morgan Chase & Co. | |
26.10.19 | UBS Neutral | Goldman Sachs Group Inc. | |
25.10.19 | Novartis Underweight | Barclays Capital | |
25.10.19 | Holcim Neutral | UBS AG | |
24.10.19 | Novartis Neutral | UBS AG | |
24.10.19 | Novartis Conviction Buy List | Goldman Sachs Group Inc. | |
24.10.19 | Novartis Conviction Buy List | Goldman Sachs Group Inc. | |
24.10.19 | ABB (Asea Brown Boveri) Underweight | JP Morgan Chase & Co. | |
23.10.19 | ams-OSRAM Underperform | Credit Suisse Group | |
23.10.19 | UBS Outperform | Credit Suisse Group | |
23.10.19 | ABB (Asea Brown Boveri) Equal-Weight | Morgan Stanley | |
23.10.19 | Novartis Neutral | Credit Suisse Group | |
23.10.19 | Novartis Underweight | Barclays Capital | |
23.10.19 | Nestlé overweight | JP Morgan Chase & Co. | |
23.10.19 | ABB (Asea Brown Boveri) Neutral | UBS AG | |
23.10.19 | UBS Sector Perform | RBC Capital Markets | |
23.10.19 | ABB (Asea Brown Boveri) Underweight | JP Morgan Chase & Co. | |
23.10.19 | Novartis Underweight | JP Morgan Chase & Co. | |
23.10.19 | ams-OSRAM Neutral | JP Morgan Chase & Co. | |
22.10.19 | Roche buy | Deutsche Bank AG | |
22.10.19 | Novartis buy | Merrill Lynch & Co., Inc. |